Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences

May 7, 2020

PRESS RELEASE Development of MammaPrint®, first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment   Irvine, California and Amsterdam, Netherlands, May 07, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that the Company’s Co-Founder and Chief…

Read more

Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients

April 16, 2020

PRESS RELEASE   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – MARCH 31, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that Translational Cancer published long term analytical performance characteristics of the 80-gene BluePrint® molecular subtyping assay. Breast cancer is a heterogeneous disease with distinct patient populations who experience…

Read more

Agendia COVID-19 Statement

March 18, 2020

As a valued customer we wanted to reach out and assure you that we are monitoring the situation regarding the outbreak of Corona Virus Disease (COVID-19) very closely; your patient’s sample and the safety of our staff is our highest priority. We are taking every measure to ensure the continued timely and high-quality handling of…

Read more

Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer

February 18, 2020

PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 13, 2020 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that BMC Cancer published results from the IMPACt…

Read more